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Abstract
The regression discontinuity (RD) design is a quasi-experimental design that estimates the causal
effects of a treatment by exploiting naturally occurring treatment rules. It can be applied in any
context where a particular treatment or intervention is administered according to a pre-specified rule
linked to a continuous variable. Such thresholds are common in primary care drug prescription where
the RD design can be used to estimate the causal effect of medication in the general population. Such
results can then be contrasted to those obtained from randomised controlled trials (RCTs) and inform
prescription policy and guidelines based on a more realistic and less expensive context. In this paper
we focus on statins, a class of cholesterol-lowering drugs, however, the methodology can be applied to
many other drugs provided these are prescribed in accordance to pre-determined guidelines. Current
NHS guidelines state that statins should be prescribed to patients with 10 year cardiovascular disease
risk scores in excess of twenty percent. If we consider patients whose risk scores are close to the
twenty percent risk score threshold we find that there is an element of random variation in both the
risk score itself and its measurement. We can therefore consider the threshold a randomising device
that assigns statin prescription to individuals just above the threshold and withholds it from those
just below. Thus we are effectively replicating the conditions of an RCT in the area around the
threshold, removing or at least mitigating confounding. We frame the RD design in the language of
conditional independence which clarifies the assumptions necessary to apply an RD design to data,
and which makes the links with instrumental variables clear. We also have context specific knowledge
about the expected sizes of the effects of statin prescription and are thus able to incorporate this into
Bayesian models by formulating informative priors on our causal parameters.
1 Introduction
The regression discontinuity (RD) design is a quasi-experimental design that estimates the causal effects
of a treatment by exploiting naturally occurring treatment rules. Since its inception in the 1960’s in
educational economics [1], the RD design has successfully been applied in areas of economics, politics,
and criminology [2, 3, 4, 5] amongst others. More recently, it has been reworked in the econometric causal
inference literature [6, 7] and there has been some interest in the design in epidemiology [8, 9] and health
economics [10].
The RD design can be applied in any context where a particular treatment or intervention is admin-
istered according to a pre-specified rule linked to a continuous variable — referred to as the assignment
variable. Such thresholds are common in many fields and, in particular, in primary care drug prescrip-
tion. For instance, according to the National Institute for Clinical Excellence (NICE) guidelines [11],
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in the UK statins (a class of cholesterol-lowering drugs) should be prescribed to patients with 10 year
cardiovascular disease (CVD) risk scores in excess of twenty percent. Consider patients whose risk scores
are close to the twenty percent risk score threshold; typically there is an element of random variation in
both the risk score itself and its measurement. Thus, we can consider the threshold to be a randomis-
ing device that assigns treatment — statin prescription — to individuals just above the threshold and
withholds treatment from those just below the threshold. In other words, if we focus on an area close
to the threshold then we have a situation that is analogous to a randomised controlled trial, resulting in
removal or mitigation of confounding where we can identify and estimate causal effects of treatments in
primary care.
The RD design can be useful in situations where evidence from randomised controlled trials (RCTs)
is available, as it is often the case that RCT results are not consistently replicated in primary care. In
such situations the RD design can shed a light on why this might be the case. In other contexts, RD
designs can confirm RCT results where other observational data might have failed to do so. Furthermore,
RD methods, whilst not providing as substantive evidence of a causal effect as an RCT, are cheaper
to implement, can be typically applied to much larger datasets and are not subject to as many ethical
constraints. This could make such methods desirable in the overall accumulation of evidence regarding the
effectiveness of a particular treatment, administered using strict prescription guidelines, on an outcome of
interest in primary care. Finally, there are many situations where RCTs cannot be run, for example, in the
case of experimental treatments for terminal diseases. The RD design means that doctors can administer
the treatments to the severely ill but still obtain a valid (if local) causal effect of the treatment, provided
they adhere to a strict guideline.
In this paper our focus is two-fold. Firstly we formulate the RD design in the framework of conditional
independence. This has, as yet, not been done and we believe that it both clarifies the underlying
assumptions and makes explicit the link with instrumental variables (IVs) of which the RD design is a
special case.
Secondly, we introduce a Bayesian analysis of the RD design based on the prescription of statins in
primary care. While Bayesian methods have been applied to the RD design, work has been principally
on spline models [12, 13]. We focus here on models incorporating prior information which have not been
widely considered, especially in primary care contexts. Since much is known already about the effect
of statins on LDL cholesterol, due principally to RCTs, we believe that this example is a good starting
point for the application of the Bayesian methods as strong prior information on the effect of statins is
available. Furthermore, as part of the analysis we are interested in estimating a causal effect for GPs who
adhere to guidelines. This requires us to think carefully about formulating priors that are informative of
the process that drives adherence. While the existence of robust information in this context facilitates
the formulation of prior models, this is by no means a pre-requisite of this methodology. We note that
our principal motivation is not to replicate the results of RCTs or to solely estimate the causal effect
of statins on LDL cholesterol using an RD design. Rather, we are interested in considering Bayesian
methodology in an RD design and use the effect of statin prescription on LDL cholesterol as a motivating
example.
We consider three models, each of which is informative to a different degree, and examine how sensitive
the results are to prior specification in datasets of different sizes. The discussion of the results highlights
the importance of thinking carefully about prior specification and also that, in some contexts, it is not
difficult to formulate reasonable prior beliefs.
We use simulated data based closely on actual statin prescriptions in the THIN primary care database
to showcase our Bayesian methodology. The simulation algorithm we develop allowed us to set the size of
the treatment effect and control the levels of unobserved confounding and the strength of the RD design.
However we were also able to retained the structure and idiosyncrasies of the original data by adding our
modifications to these data rather than simulating it in its entirety.
The paper is organised in three parts: in the first one, section 2, we first describe the RD design
in more detail and introduce the running example (statins prescription for the primary care prevention
of cardiovascular disease). Then, we formalise the assumptions necessary to identify a causal treatment
effect using the RD design. Finally, we clarify the links between the RD design and instrumental variables
and introduce the causal estimators.
The second part of the paper (section 3) introduces the details of our novel Bayesian model formu-
lation. In this section, we describe and justify all the distributional assumptions used in our model and
discuss the implications of incorporating prior clinical knowledge in causal analyses, specifically when
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they are based on the RD design.
Finally, in the third part of the paper (sections 4 and 5) we introduce a simulation study, providing
details of the simulation strategy as well as the results of the application of our models to the simulated
data. Problems and extensions are discussed in section 6.
2 The regression discontinuity design
2.1 The basics of the RD design
In its original inception, the RD design was used to evaluate the effect of schooling on a number of
adult life outcomes e.g. income. The classic example considers scholarships that are offered to students
according to their grade-point-average or other markers of academic/sporting ability. However, the RD
design can be applied in any context where an intervention, be it a drug, a lifestyle modification, or other,
is administered according to guidelines based on continuous variables.
These situations also arise commonly in primary care drug prescription: examples include the pre-
scription of anti-hypertensive drugs when blood pressure exceeds 140/90mmHg1 or of selective serotonin
reuptake inhibitors for patients exhibiting more than 4 symptoms in the ICD-10 classification of depres-
sion. Another interesting case, which we use as a running-example in this paper, is the prescription
of statins, a class of cholesterol-lowering drugs, in the primary prevention of cardiovascular disease, in
the UK. There are clear NICE guidelines regarding statin prescription [11], which makes this a suitable
case-study to show the potential of the RD design to perform a causal analysis using primary care data.
In the case of statins, the guidelines recommend that individuals who have not experienced a cardiac
event should be treated if their risk of developing cardiovascular diseases (CVD) in the subsequent 10
years, as predicted by an appropriate risk calculator (e.g. Framingham risk calculator), exceeds 20%.
Note that in the original NICE guideline, the choice of the threshold was driven also by cost-effectiveness
considerations.
A 10 year cardiovascular risk score is predicted based on a logistic regression with a number of clinical
and lifestyle factors. These typically include, amongst others, blood pressure, total cholesterol, smoking
status. Thus the RD design can be used to estimate the effect of statins on clinical outcomes, specifically
LDL cholesterol levels, in individuals around this threshold level.
2.1.1 The sharp RD design
In an ideal situation, all general practitioners (GPs, UK family doctors) prescribe statins to patients who
have a risk score above the 20% risk score threshold and do not prescribe the drugs to those whose risk
score falls below 20%. In addition, if statins also have a positive effect (i.e. they reduce LDL cholesterol)
then a plot of risk score versus LDL cholesterol could look like Figure 1(a), particularly if cholesterol
is linear in the risk score. Here, circles represent untreated patients and crosses treated patients. The
“jump” at the 20% risk score can then be interpreted as the average treatment effect at the threshold.
If we assume that the effect of statins is constant across risk scores i.e. that the slope of the regression
of LDL cholesterol against risk score is the same above and below the threshold then the effect at the
threshold can be considered an average effect for all risk scores as in Figure 1(b). It is possible however,
that the slopes differ depending on whether the patient is above or below the threshold. In this case, the
scatter plot of LDL cholesterol against risk score might look like Figure 1(c).
In this situation, where thresholds are strictly adhered to the RD design is termed sharp and the
value of the jump is estimated and interpreted as the causal effect.
2.1.2 The fuzzy RD design
Typically in most applications, and particularly in the case of statin prescription, the RD design is not
sharp. This is because GPs will often prescribe statins to patients below the threshold if they deem
that it will be beneficial or possibly not prescribe statins to patients above the threshold if statins are
counter-indicated for these patients. We term this GP adherence to the guidelines. We contrast this
to the situation where patients are not complying to treatment prescribed. We make this distinction in
order to avoid confusion by using the term compliance to describe the GP’s behaviour when typically
this term is used to describe patients’ behaviour. For the remainder of the paper and, in particular, for
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Figure 1: (a) The sharp RD design with crosses indicating patients who have been prescribed statins and
circles those who have not, (b) The sharp RD design with equal slopes with regression lines above and
below the threshold and a bold vertical bar at the threshold to indicate the effect size, (c) The sharp
design with different slopes, (d) The fuzzy design. Note that there are crosses below and circles above
the threshold indicating that some GPs are not adhering to the treatment guidelines.
the simulations, we assume that patients comply to their prescription. In Section 6 we briefly highlight
differences between these two types of compliance and discuss how we might account for patient non-
compliance in the real data. When GPs do not adhere to treatment guidelines, a plot of risk score
against cholesterol might look like Figure 1(d) where the crosses below the threshold and circles above
the threshold indicate individuals who are not being prescribed according to the guidelines. In this
situation the RD design is termed fuzzy. In order to estimate treatment effects (typically local/complier
effects) additional assumptions must be made as detailed in Section 2.2 below.
2.2 Assumptions
A number of assumptions must hold in order for the RD design to lead to the identification of causal
effects. These assumptions are expressed in different ways depending on the discipline [6, 14, 7]. We
describe our approach in the language of conditional independence [15, 16, 17]: in our view, this approach
helps to clarify situations where the RD design can be used and highlights the links with the theory of
instrumental variables. Throughout the paper, we follow standard notation: if a variable A is independent
of another B conditional on a third C, then p(A,B | C) = p(A | C)p(B | C) and we write A⊥⊥B | C [16].
Let X be the assignment variable on which the treatment guidelines are based. Specifically, if x0 is
the threshold given by the treatment guidelines, then let Z be the threshold indicator such that Z = 1
if X > x0 and Z = 0 if X ≤ x0. Furthermore, let T indicate the treatment administered (prescribed);
we assume a binary treatment, so that T = 1 means treatment is administered (prescribed) and T = 0
means it is not. Also, let C = {O∪U} be the set of confounders, where O and U indicate fully observed
and partially or fully unobserved variables, respectively. Finally, Y is the continuous outcome variable.
In our case study, X is the 10 year cardiovascular risk score with x0 = 0.2. Thus Z = 1 if a patient’s 10
year risk score exceeds 0.2 and 0 if their score is below 0.2. The treatment is statin prescription (NB: not
patient taking the treatment). The outcome of interest is the level of LDL cholesterol.
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We discuss in detail the assumptions necessary for the RD design, below.
A1. Association of treatment with threshold indicator :
Treatment assignment must be associated with the treatment guidelines. This assumption can be
expressed equivalently as
Z 6⊥⊥T,
which implies that Z and T are not marginally independent. In the context of statin prescription
this assumption will hold if the GPs adhere to the NICE treatment guidelines and Z is predictive
of treatment T , i.e. they prescribe the treatment to patients with a 10 year risk score that exceeds
20% and do not prescribe statins to patients whose risk score is below 20%. This assumption can
be tested directly by estimating the association between Z and T . This does not mean that the RD
design breaks down when GPs prescribe according to their own criteria, as the guideline itself is still
in place. What happens if some GPs prescribe according to their own criteria is that assumption
A1 becomes weaker as the association between the threshold indicator (i.e. the guideline) and
prescription practice decreases. However, provided the association is still strong, i.e. a sufficient
number of GPs adhere to it, fuzzy methods can be brought to bear.
A2. Independence of guidelines:
The treatment guidelines cannot depend on any of the characteristics of the patient (excluding X),
i.e. they cannot be changed for individual patients. We can express this assumption in terms of
the threshold indicator as
Z⊥⊥C,
i.e. Z is marginally independent of C — and we note that this should hold at least around the
threshold. We can also see this assumption as meaning that the patient characteristics (excluding
X) cannot determine their value of Z.
Assumption A2 does not preclude dynamic treatment strategies as long as these are pre-specified.
We could consider a dynamic strategy as one that depends not only on the risk score but on a
number of factors. For instance, a GP might look at a fixed number of (observed and recorded)
risk factors when deciding whether to prescribe statins and only prescribe when a pre-specified
minimum number indicate elevated risk. This will be different for each patient but will not be
different for two patients with the same values for the risk factors.
If the threshold indicator is associated with some unobserved confounders U , a weaker version of
this assumption is that the threshold indicator does not depend on the unobserved confounders
given the observed confounders O
Z⊥⊥U | O.
We can think of this as the RD design applied within strata of the observed confounders, for example
by considering statin prescription for men only.
Neither version of A2 can be tested as each involves either implicitly or explicitly the unobserved
confounders U . However, A2 is likely to hold in one of the two forms, because it is typically
externally imposed and does not vary from patient to patient or from one GP to another.
A3. Unconfoundedness:
In order for the RD design to be a valid randomisation device, the outcome must be independent of
the threshold indicator, conditionally on the other variables. This can be expressed more formally
as
Y⊥⊥Z | (T,C). (1)
For the statin example, this requires that patients cannot determine their treatment assignment,
i.e. that even when they know about the treatment rule, they cannot manipulate their outcome in
order to fall above or below the treatment threshold. This guarantees that there is some randomness
in where subjects fall with respect to the threshold. While it is plausible for patients to try and
persuade their GPs to prescribe statins when they do not have a high enough risk score, this is
unlikely to happen in a systematic manner and can also be subsumed in a weakening of assumption
A1. Nevertheless, (1) breaks down if the GPs systematically fail to adhere to the risk score guideline
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but rather base treatment decisions on unobserved factors. As total cholesterol is part of the
risk factor and LDL cholesterol is in turn a part of the total cholesterol, it might appear that
assumption A3 does not hold. However, total cholesterol also includes HDL cholesterol and the
risk score contains a number of other factors. Thus the link between Y and Z in our example is
not deterministic but subject to random variation generally and most importantly for individuals
around the threshold, C will contain all the remaining confounders such as HDL cholesterol and
thus there will be no direct link.
The condition in (1) is also untestable as it too implicitly involves the unobserved confounders U .
It is therefore important to consider whether individuals on either side of the threshold really can
be considered to be exchangeable.
A4. Continuity :
It is necessary to assume that, conditionally on the other variables, the expected outcome is con-
tinuous around the threshold x0. This can be expressed in terms of
E(Y | Z,X = x, T,C) is continuous in x (at x0) for T = 0, 1.
To understand why this assumption is necessary note that the marginal expectation of the outcome,
conditionally on the assignment variable alone, i.e. E(Y | X = x), is in fact discontinuous around
the threshold and it is the size of the discontinuity that is interpreted as a causal effect. The
continuity of the conditional expectation guarantees that it is the threshold indicator and not any
of the other variables that is responsible for the discontinuity in the outcome. Some RD design
texts [7], state this assumption in terms of the the limits from above and below of the expectation of
Y . More generally, we can assume that the conditional distribution of Y given the two treatments
(active and control) and the assignment is continuous at the threshold [6]. This assumption is
partly testable on the observed confounders O, e.g. if partial regression plots of the outcome against
observed confounders conditional on the assignment exhibit discontinuities around the threshold,
then assumption A4 is called into question.
In the context of statin prescription, this assumption requires that the expected value of LDL
cholesterol as a function of variables other than the risk be continuous. If there were a discontinuity
in the association between LDL cholesterol and, for instance, body mass index (BMI) conditionally
on the risk score being 20%, then it would not be possible to attribute the jump in LDL cholesterol
to the threshold indicator and as a consequence the treatment. In particular, if BMI is a confounder
for the relationship between risk score and LDL cholesterol, it would follow that the discontinuity
observed in LDL cholesterol could be due to BMI.
A5. Monotonicity (fuzzy design only):
For the fuzzy design, another assumption is necessary in order to identify a local causal effect rather
than an average effect (we formally define these in Section 2.3 below). This assumption requires
that there are no GPs who systematically prescribe the opposite of what the guidelines recommend.
We define the pair of prescription strategies that a GP has prior to seeing a patient as (Sa, Sb), for
above and below the threshold, respectively. These are binary decision variables taking value 1 if the
GP prescribes the treatment and 0 otherwise. Then we can express the monotonicity assumption
as
Pr(Sa = 0, Sb = 1) = 0,
i.e. the probability of there being GPs who would decide to prescribe the treatment to all individuals
below the threshold and who would decide not to prescribe the treatment to individuals above the
threshold is 0. We must also assume that the GPs act according to these prescription strategies. In
the potential responses literature this is often referred to as the “no defiers” assumption. There are
a number of weaker versions of the monotonicity assumption (see, for example, [18, 19]) which are
plausible in some RD design settings when the strong assumption given above cannot be assumed
to hold.
In the context of our running example, this seems a very plausible assumption: even if a GP is not
in agreement with the guidelines, he or she will be concerned with patient benefit rather than in
compliance with NICE recommendations. However, if we allow for patient non-compliance to the
treatment, then the monotonicity assumption implies that there are no patients who on principle
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will decide to do the opposite of what they are prescribed. It is likely that there are some of these
patients in a real context and thus the weaker assumptions can be invoked. We discuss these briefly
in Section 6. It is not generally possible to test this assumption unless we are able to inquire of
GPs or patients how their decision strategy is formulated.
2.3 Links with IV and causal effect estimators
It is well-known that the RD design threshold indicator Z is a special case of a binary instrumental variable
[6, 17].We link the RD design to the IV framework using the language of conditional independence and
thereby clarify how the RD design fits into the context of experiments and quasi-experiments.
Consider the case of a binary treatment (e.g. an active drug treatment versus a placebo) and the
two experimental designs commonly used for causal inference. The first is the “gold standard”, the
double blinded randomised controlled trial with perfect compliance (henceforth RCT), meaning that the
individuals in the trial take exactly and only the treatment to which they have been assigned. The second
is the randomised controlled Trial but with Partial Compliance (henceforth TPC), meaning that not all
the individuals take the treatment they have been assigned.
In the RCT it is possible to estimate the average treatment (causal) effect
ATE = E(Y | T = 1)− E(Y | T = 0)
= E(Y | Z = 1)− E(Y | Z = 0), (2)
without making additional assumptions, since randomisation and perfect compliance guarantee (bar
unlucky and unlikely lack of balancing) that any difference in the outcome is due only to the treatment
assigned.
However, in the TPC an average causal effect cannot be estimated because there is confounding by
treatment self-administration. This means that some patients in the treatment arm (and we typically do
not know which ones) have not actually taken the treatment or, conversely (and often less likely), that
some of the patients in the control arm have obtained the treatment and taken it. We will not know what
motivated the patients to act as they did and thus an intention-to-treat effect will typically be a biased
estimate of the average treatment effect.
In these situations, a local (sometimes called a complier) average treatment effect
LATE =
E(Y | Z = 1)− E(Y | Z = 0)
E(T | Z = 1)− E(T | Z = 0) . (3)
is estimated using the treatment assignment as an IV. In order to make the LATE identifiable, it is
necessary that the RD monotonicity assumption A5 holds.
By comparing the RD design to the RCT and TPC scenarios described above, we see that the RD
sharp design is analogous to the RCT and that the fuzzy RD design is analogous to the TPC with
the treatment assignment corresponding to the threshold indicator. Thus, in a sharp RD the ATE is
equivalent to (2), while for the case of the fuzzy design, where the threshold guidelines are not always
adhered to, the LATE is a measure of the threshold effect with the threshold indicator as an IV.
This correspondence highlights the appropriateness of the ATE and LATE as causal effect estimates
in the primary care context. The ATE is clearly the appropriate causal estimate for the sharp design
as this is equivalent to the RCT. For the fuzzy design, the ATE as shown in (2) corresponds to the the
intention-to-treat (ITT) estimator in a TPC. This ITT estimator is subject to confounding and does not
identify a causal effect. Therefore the LATE is typically identified in TPCs as and is thus appropriate
for the fuzzy RD.
In our context, the LATE identifies the causal effect for those patients registered with GPs whose
prescription strategy corresponds with NICE guidelines. We have no reason to believe that the types
of patients registered with such GPs are systematically different to the patients of GPs whose strategies
are different. Thus we believe that the LATE provides us with a valid and potentially generalisable
causal effect estimate. A further discussion, involving lack of patient compliance to treatment is given in
Section 6.
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3 Bayesian model specification
Our motivation for using Bayesian methods to analyse data generated in a RD setting, is three-fold.
Firstly, the Bayesian framework enables us to set priors in such a way as to reflect our beliefs about the
values of the parameters and potentially impose substantively meaningful constraints on their values.
For example, given extensive RCT literature [20], it is widely accepted that the effect of statin treatment
is a decrease in LDL cholesterol of about 2 mmol/l. When modelling the LATE, we can parameterise
the numerator (i.e. the sharp treatment effect ATE) in such a way as to express this belief, while still
allowing for uncertainty around this informed prior guess. We discuss strategies for achieving this goal
in Section 3.2.
A second reason for adopting a Bayesian approach is that, when estimating the LATE, a major
concern is that the denominator, that is, the difference between the probabilities of treatment above and
below the threshold, can be very small at the threshold (i.e. when the threshold is a weak instrument).
The Bayesian framework allows us to place prior distributions on the relevant parameters in such a way
that the difference must exceed a certain minimum or such that the difference is “encouraged” to exceed
a certain minimum. This can stabilise the LATE estimate, as we discuss in Section 3.3.
Finally, standard frequentist methods rely on complex asymptotic arguments to estimate the vari-
ance associated with the treatment effect, which often results in overly conservative interval estimations.
By contrast, Bayesian analyses are typically implemented using MCMC methods, which allow increased
flexibility on the modelling structure, as well as relatively straightforward estimation for all the rele-
vant quantities (either directly specified as the parameters of the model, or derived using deterministic
relationships among them).
The inclusion of (relatively) strong prior information makes sense especially in contexts where the
signal in the data is particularly weak and confounded and when, as in the RD design context, information
about both the drug treatment and the probability of treatment above and below the threshold is available
through previous research and extensive content-matter knowledge. We discuss the strength of effect of
the prior information when looking at the results of the analysis and the simulation studies, as well as to
what extent results from these studies can be considered reliable in Section 4.
As the results appear to be more sensitive to priors on the denominator of the LATE, we summarise
the priors for the ATE briefly in Section 3.2 before tackling the prior models on the denominator in more
detail in 3.3.
3.1 Local linear regression
The estimators we consider depend on linearity assumptions which do not always hold for the whole
range of the threshold variable. This can put too much weight on data far from the threshold, thereby
resulting in biased estimates. In this case, we can either consider more flexible estimators such as splines
or we can explore local linear regression (LLR) estimators.
LLR estimates are obtained using data only within some fixed bandwidth, h, either side of the
threshold. This achieves three aims: (i) to use data around the threshold so that points further away
have little or no influence on the predictions at the threshold; (ii) to make linearity assumptions more
plausible, as a smaller range of points is used, which belong to an area where linearity is more likely to
hold; (iii) to obtain smooth estimates. There are some recommendations in the literature regarding the
optimal size of a bandwidth [6], however these appear somewhat arbitrary.
3.2 Models for the ATE
In line with equation (2), we estimate the average LDL cholesterol level as a function of the threshold
indicator. First, we model the observed LDL cholesterol level separately for the individuals below (whom
we indicate with l = b) and above (l = a) the threshold, as
yil ∼ Normal(µil, σ2)
and specify a regression on the means
µil = β0l + β1lx
c
il, (4)
where xcil is the centered distance from the threshold x0 for the i−th individual in group l.
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Obviously, the observed value of xcil determines whether, under perfect GP adherence, the individual
is given the treatment or not. Thus, for l = a, b, the expressions in (4) are equivalent to E(Y | Z = 1)
and E(Y | Z = 0) respectively, and the ATE may be written
ATE = ∆β =: β0a − β0b, (5)
that is the difference in the two averages at the threshold, i.e. when xcil = 0.
Within the Bayesian approach, to complete the model specification we also need to assign suitable
prior distributions to the parameters (β0l, β1l, σ
2). Where possible, we use the information at our disposal
to assign the values of the priors for the model parameters. For example, we know the plausible ranges
of the risk score and the LDL cholesterol. We also know from previous studies, trials and conversations
with clinicians, that LDL cholesterol increases with risk score and that once statins are taken, the LDL
cholesterol tends to decrease. We attempt to encode this information in the priors below.
With (at least moderately) large datasets, the posterior inference is less sensitive to the distributional
assumptions selected for the variance σ2, because there is enough information from the observed data to
inform its posterior distribution. As a result, we consider a relatively vague uniform prior on the standard
deviation scale: σ ∼ Uniform(0, 5).
We consider the following specification for the coefficients for the regression models above and below
the threshold:
β0b ∼ Normal(m0, s20) and β1b ∼ Normal(m1b, s21b) (6)
β0a = β0b + φ and β1a ∼ Normal(m1a, s21a). (7)
The priors on the parameters β0b and β1l for l ∈ {a, b} are chosen so such that they result in LDL
cholesterol levels that are with plausible values for the observed range of risk scores. This can be achieved
by selecting suitable values for the hyper-parameters (m0,m1b,m1a, s
2
0, s
2
1b, s
2
1a)
1.
The parameter φ represents the difference between the intercepts at the threshold, i.e. “jump” due to
the causal effect of the treatment. We consider two different specifications for φ upon varying the levels
of informativeness on the prior distribution
φwip ∼ Normal(0, 2) and φsip ∼ Normal(−2, 1)
The former assumes that on average, the treatment effect is null as the magnitude of the prior variance
is in this case large enough that the data can overwhelm the null expectation and thus we identify it as
weakly informative prior (wip). We indicate with the notation ∆wipβ the ATE estimator expressed in the
form of equation (5) resulting from this formulation of the priors.
In the latter, we encode information coming from previously observed evidence that statins tend to
have an effect of around 2 mmol/l at the threshold. In this particular case study, given the extensive
body of RCTs on the effectiveness of statins, we set the variance to 1, which essentially implies relatively
strong belief in this hypothesis. We term this the strongly informative prior (sip) and the resulting ATE
estimator is ∆sipβ .
3.3 Models for the denominator of the LATE
Since we know that in clinical practice there is a clear possibility that the assignment to treatment does
not strictly follow the guidelines, as there may be other factors affecting GPs decisions, we also construct
a suitable model to compute the LATE estimator. To do so, we need to estimate the denominator of
equation (3). We start by considering the total number of subjects treated on either side of the threshold,
which we model for l ∈ {a, b} as
nl∑
i=1
til ∼ Binomial(nl, pil),
1For instance, selecting m0 = 3.7, m1b = 8, s0 = 0.5 and s1b = 0.75 implies that the prior 95% credible interval for
the estimated LDL level ranges in [2.57; 4.83]mmol/l for individuals with a risk score of 0 and in [2.72; 4.68]mmol/l for
individuals close to the threshold. For the slope β1a above the threshold, we encode the assumption that the treatment
effect is subject to a form of “plateau”, whereby for individuals with very high risk score, the effect is marginally lower than
for those closer to the threshold. See the online supplementary material for details.
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where nl is the sample size in either group. The quantities pia and pib represent E(T | Z = 1) and
E(T | Z = 0), respectively and thus can be used to estimate the denominator of equation (3) as
∆pi =: pia − pib. (8)
As we have little information, a priori, on the probabilities of prescription above and below the threshold,
we consider three different prior specifications for the parameters pil, leading to three possible versions of
the denominator ∆pi. We investigate the sensitivity of results to different beliefs regarding the strength
of the threshold instrument by acting on the difference ∆pi directly.
3.3.1 Unconstrained prior for (pia, pib)
First, we consider a simple structure, in which the probabilities on either side of the threshold are modelled
using vague and independent prior specifications. For convenience, we use conjugate Beta distributions
that are spread over the entire [0; 1] range
pil ∼ Beta(1, 1).
Since this specification does not impose any real restriction on the estimation of the probabilities pil, we
term this model unconstrained (unc) and we indicate the denominator resulting from the application of
(8) under this prior as ∆uncpi .
3.3.2 Fixed difference prior for (pia, pib)
Next, we show how to build priors that effectively impose a sharp design on the data. This means that
pia 6= pib and the LATE estimator does not “explode”.
We consider a structure that implies a fixed distance between pia and pib — consequently we termed this
the fixed difference prior (fix ). The idea is to use informative and correlated conjugate Beta distributions
linking pia and pib, specifically in the form
pib ∼ Beta(αb, [nb + 1])
pia ∼ Beta(αa, 1)
αb ∼ Uniform(1, 100000)
αa = ν + αb
ν ∼ Uniform(200, 10000).
Since the parameters of the Beta distribution can be thought of as representing the prior number of
“successes”−1 and “failures”−1 respectively, the prior for pib encodes the (extreme and simplistic) as-
sumption that all nb subjects below the threshold are untreated, i.e. all of the observed untreated.
Similarly, the prior for pia implies that there are no untreated above the threshold. In addition, we are
also imposing at least 200 more treated above than below, by modelling the parameter ν uniformly in
the range [200; 10000]. As a consequence, we imply that the resulting denominator (which we indicate as
∆fixpi , under this formulation) has a minimum value which depends on the size of the bandwidth through
the sample size nb.
This model is, in fact, quite strict as it imposes in the prior a situation that is very similar to a sharp
RD design and thus it would not be a very sensible choice in a “real” analysis — but we consider it here
to investigate the effect of an extreme prior specification on the results.
3.3.3 Flexible difference prior for (pia, pib)
Finally, we construct a model in which prior information is used in order to “encourage” a significant
difference between the probabilities — we term this the flexible difference prior (fdp) and define it as
logit(pia) ∼ Normal(2, 1) and logit(pib) ∼ Normal(−2, 1)
These priors imply that, effectively, we assume the probability of treatment below the threshold to be
substantially lower than 0.5 (i.e. most of the probability mass is concentrated in the range [0, 0.5],
while still allowing for a small chance of exceeding this interval). Similarly, we assume that most of the
probability mass for pia is above the cut-off value of 0.5, as shown in Figure 2. In this way, we limit the
possibility that the two quantities are the same, a priori, while not fixing a set difference between them.
The denominator derived using these prior assumptions is indicated by ∆fdppi .
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Prior density estimates for probability of treatment
 above and below the threshold
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Figure 2: Prior predictive distribution for the probability of treatment below (solid line) and above
(dashed line) induced by the flexible difference model. The former is substantially lower than the cut-off
value of 0.5, while the latter mostly exceeds this. Nevertheless, both allow for the full range of values in
[0; 1] to be possible
3.4 Models for the LATE
It is easy to obtain suitable estimates for the LATE by simply combining the models of §3.2 and §3.3.
We tried a number of combinations of different specifications. Eventually, we chose three as they were
representative of the results. In all cases, the numeerator is given by ∆sip as the results were not sensitive
to changes in the ATE. We combined
• the fixed difference model in the denominator with the strongly informative prior model for the
ATE and termed this the constrained model
LATEcnst =
∆sipβ
∆fixpi
;
• the flexible difference model in the denominator with the strongly informative prior in the numerator
and term this the flexible model
LATEflex =
∆sipβ
∆fdppi
;
• the unconstrained denominator with the strongly informative prior in the numerator and term this
the unconstrained model
LATEunct =
∆sipβ
∆uncpi
.
4 Simulated data
We consider the simulation of data for which an RD design would be appropriate. We are interested in
testing our methodology on data that are as close as possible to the data on primary care prescriptions.
One reason is that results based on realistic data, with all its idiosyncrasies and quirks, are potentially
of more value than simulations based on pre-specified regression models. Another reason is that these
data retain the basic structure of the original data so that the ranges of the variables of interest, LDL
cholesterol levels, risk scores etc. are, for the most part, within the true levels of these variables. This
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means that it makes sense to think about prior information for the simulated data in much the same way
as one would for the real data as it is as noisy as the real data and retains its quirks. See Jones et al.
[21] for examples of Bayesian methods for weak IVs which use data simulated from the ground up.
Specifically we base our simulation scheme on The Health Improvement Network (THIN) dataset (see
www.thin-uk.com). The THIN database is one of the largest sources of primary care data in the United
Kingdom and consists of routine, anonymised, patient data collected at 497 GP practices. Broadly, the
dataset is representative of the general UK population and contains patient demographics and health
records together with prescription and therapy records, recorded longitudinally. Our aim is to use the
models presented in Section 3 to estimate a pre-defined treatment effect of the prescription of statins on
LDL cholesterol level (mmol/L). We base our simulation scheme on a subset of data from THIN consisting
of males only aged over 50 years (N = 5720 records). It is important to consider the assumptions
presented in Section 2.2 whilst ensuring that the characteristics of the simulated data reflect the original
observations. With this in mind, our simulation method can be split broadly into two parts.
The first part concerns the adjustment of the original subset from THIN to remove any pre-existing
treatment effect and the simulation of a treatment indicator. This is done in an effort to ensure that any
differences between these groups are due mainly to the assignment of treatment to one group during the
simulation algorithm. The second part concerns the simulation of the outcome (LDL cholesterol level).
As previously described in Section 2.2, we use a threshold of a 0.2 10-year cardiovascular risk score.
We also include extra randomness at various points in the simulation algorithm, which is described in
Sections 4.1 and 4.2 below. A flow-diagram describing the main steps is displayed in Figure 3.
We note here that our simulation method is carefully constructed and somewhat different from that
seen in many simulation studies. This is done so that the simulated data retains much of the variability
present in the original data upon which the simulations are based. One of our main aims is to consider
RD designs that could be fitted to real-life observational data and so we feel it is important that the
simulated data reflect this.
4.1 Simulation algorithm: Part I (simulating the treatment)
1. From the available subsample of THIN, we consider, for the i−th individual, the following observed
variables: xci as the centered version of the 10-year cardiovascular risk score; zi as the threshold
indicator, such that zi = 1 if x
c
i > 0 (i.e. if the uncentered risk score xi > 0.2) and zi = 0 otherwise;
ti as the treatment indicator, where ti = 1 if the individual receives statins and ti = 0 otherwise; ai
as the observed age; di as an indicator of diabetes, taking value 1 if the i−th individual is diabetic
and 0 otherwise; hi as the individual HDL cholesterol level (measured in mmol/l); and yi as the
individual’s LDL cholesterol level. These are the starting point for our simulations.
2. We then remove any pre-existing effects of treatment and threshold on the outcome yi. This will
allow the comparison of estimated results to a known, pre-specified, treatment effect (which we
describe in Part II) as well as justifying the assumption that the outcome does not depend on the
threshold. We fit the normal linear model:
yi = α0 + α1ti + α2zi + ε1i (9)
with the ε1i (i ∈ {1, . . . , N}) independent, normal, zero mean error terms with a constant variance.
We define y to be the vector of observed LDL cholesterol values, with sample mean y¯, and yˆ as
the vector of fitted values from the model (9). We draw a new set of simulated LDL cholesterol
outcome values, denoted ySIM1 such that, for i = 1, . . . , N :
ySIM1i = yi − yˆi + wi
with wi drawn at random from a Normal(y¯, 0.1
2) distribution. We add the wi term so that y
SIM1
i
has approximately the same expectation as Yi with the variance term included to reflect additional
uncertainty in ySIM1i but still reasonably small because we do not expect y
SIM1
i to differ too greatly
from yi. A normal distribution is assumed for LDL cholesterol values, in general, throughout.
3. At this point, we define the individual probability of treatment pi = Pr(Ti = 1) and fit the following
generalised linear model:
log
(
pi
1− pi
)
= α3 + α4ai + α5di + α6x
c
i + α7hi + α8zi.
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Part I, 1. Select real data sample and define variables to be used.
Part I, 2. Remove any existing observed treat-
ment effect in the data sample and obtain ySIM1.
ySIM1 has the same expectation as y the observed LDL choles-
terol but without association with treatment or threshold
Part I, 3. Fit a glm for P(Treatment) using the real data.
Part I, 4. Use this glm to estimate P(Treatment), pˆ,
adjusting model parameters pertaining to HDL choles-
terol level and threshold to obtain the desired level of un-
observed confounding and threshold instrument strength.
Hence draw an estimated treatment indicator for each individual, tˆi.
Part II, 1. Regress LDL cholesterol level ySIM1
on estimated treatment indicator, keeping the
estimated residuals from the fitted model: εˆ2i
Part II, 2. Regress residuals, εˆ2i, from the above model on risk
score, age and a diabetes indicator. Use the fitted values from
this model to distort the LDL cholesterol values to obtain ySIM2
Part II, 3. Add a treatment effect on LDL cholesterol level
ySIM2 with desired expected value τ when tˆi = 1 to ob-
tain ySIM3 the final simulated value of LDL cholesterol
Figure 3: A flow-diagram describing the main steps in the simulation algorithm.
Let αˆ denote the estimates from the fitted model with corresponding estimated covariance matrix
Σα. We re-draw the parameter estimates from a Normal(αˆ,Σα) distribution, which we indicate as
α˜. This is usually done when imputing data to reflect our uncertainty in the estimated values of α.
We replace α˜7 and α˜8 with pre-specified values to adjust the level of confounding and the strength
of threshold as an instrument for treatment, respectively, in the simulated dataset.
4. For each individual, we estimate pi (denoting the estimate pˆi) and randomly draw an estimated
treatment variable, tˆi from a Bernoulli(pˆi) distribution.
4.2 Simulation algorithm: Part II (simulating the outcome)
1. From Part I, we form the following normal linear model for the adjusted LDL cholesterol values
ySIM1i = γ0 + γ1tˆi + ε2i,
with the ε2i (i ∈ {1, . . . , N}) independent normal, zero mean, error terms with a constant variance.
We also obtain the vector of estimated residuals, εˆ2.
2. We fit the normal linear model:
εˆ2i = γ2 + γ3ai + γ4di + γ5x
c
i + ε3i
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with the ε3i (i ∈ {1, . . . , N}) independent, normal, zero mean error terms with a constant variance.
We calculate the vector of fitted values from this model and add to each fitted value its corresponding
standard error estimate, denoting the resulting vector ε˜2. This is done to slightly perturb the fitted
values of ε2, incorporating additional randomness and uncertainty into the estimated values. We
then add this ε2 to y
SIM1 to form a slightly distorted vector of simulated LDL cholesterol values,
which we denote as ySIM2.
3. Finally, we add a treatment effect of a pre-specified size, τ by defining:
ySIM3i = y
SIM2
i + (1− tˆi)v1i + tˆiv2i,
where v1i ∼ Normal(0, 0.52) and v2i ∼ Normal(τ, 0.52). The resulting vector ySIM3 is a set of
simulated LDL cholesterol values with a treatment effect of size τ for the treated. A relatively
small variance of 0.25 is chosen here so that the treatment effect can be distinguished.
4.3 Unobserved Confounding
We aim to examine the properties of the estimators presented in Section 3 under varying levels of un-
observed confounding. We use the HDL cholesterol level as an unobserved confounder because it is
predictive of both LDL cholesterol and treatment. There are, of course, many other variables that could
have been included in the regression models we used to formulate the simulated outcomes, but for the
sake of simplicity we only considered one confounder at this stage.
The estimated correlation between the LDL and HDL cholesterol levels is 0.18 in the original dataset
and, to increase unobserved confounding, we also use an adjusted dataset as a basis for simulation,
where the estimated correlation between the LDL and HDL cholesterol levels is augmented to 0.5. In
addition, the level of unobserved confounding is adjusted in Step 3 of Part I of the simulation algorithm,
when the value of α˜7 is selected. Given these two ways of manipulating the relationship between HDL
cholesterol, treatment probability and LDL cholesterol, we define four levels of unobserved confounding,
where unobserved confounding increases with level number. The levels are determined by the values
of r = Corr(HDL, LDL) in the simulated data and α˜7 in Step 3 of the simulation algorithm (Part I)
and we list them according to (r, α˜7) as: Confounding Level 1 (0.18, 4), Confounding Level 2 (0.5, 4),
Confounding Level 3 (0.18, -2) and Confounding Level 4 (0.5, -2).
The scenarios identifying confounding level 3 and 4 above correlate higher HDL cholesterol with
lower probability of being treated, whilst maintaining the positive correlation between HDL and LDL
cholesterol. Thus, the effect of the confounder acts in opposite directions on the probability of treatment
and the size of the outcome. This is not entirely realistic in the context of statin prescription; nevertheless,
we are interested in assessing the performance of the estimators even in such an extreme scenario. Simple
plots of the risk score against LDL cholesterol level that identify treated and untreated patients, such as
those in Figures 4 and 5 (Column 1), are useful in assessing the level of compliance of a GPs within a
particular dataset.
4.4 Threshold as an Instrumental Variable
In our analysis, we consider cases in which the threshold acts as either a strong or a weak instrumental
variable for the treatment. This is achieved through the pre-defined choice of α˜8 in Step 3 of Part I
of the simulation algorithm. In particular, α˜8 = 10 and α˜8 = 4 are chosen to imply a strong and a
weak instrument, respectively. When α˜8 = 10, the probability of being treated is almost certain above
the threshold, however, when α˜8 = 4 the effect of the instrument is of the same order as that of the
confounders, and the probability of being treated is much smaller.
5 Results
We simulated 100 datasets using the algorithm described in Section 4 and fitted models using each of
them. It is often not clear whether or not there exists a discontinuity at particular threshold, especially
when data are very variable. We investigated this further by producing plots of the raw data points
(continuous threshold variable against outcome) and by producing plots showing outcome mean estimate
and raw probability of treatment estimate within regular bin widths defined by the threshold variable (in
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this case, the risk score). This is a common initial exploratory analysis when an RD design is thought
to be appropriate and is typically used as a tool to back up the assumptions which determine whether
or not an RD design is valid [6, 4, 14, 22]. Figures 4 and 5 show such plots produced using one of the
simulated datasets described above, under each defined level of unobserved confounding and instrument
strength for the design threshold. In each case the treatment effect size is 2. The plots in Figure 4 were
produced using datasets in which threshold is a strong instrument for treatment, whereas Figure 5 was
produced using datasets where threshold is a weak instrument for treatment. The raw plots (left-hand
column) show clearly that the RD design becomes more fuzzy as confounding increases, especially where
the threshold is a weak instrument for treatment. The plots of the mean outcomes (central column) and
estimated probabilities of treatment (right-hand column) show obvious discontinuities at the threshold
value of 0.2, except in Figure 5 where the level of unobserved confounding is high (levels 3 or 4). The
discontinuities are generally larger for lower levels of unobserved confounding. When plots of either the
estimated outcome means or raw estimates of probability of treatment – within risk score bins – exhibit
a jump in at the threshold, then there is some evidence to suggest the use of the RD design may be
appropriate. In light of these initial plots, an attempt to implement the RD design appears reasonable
in all scenarios except where threshold is a weak instrument for treatment and unobserved confounding
is thought to be at a high level. We performed analyses using RD designs on each of the 100 simulated
datasets for all levels of unobserved confounding and instrument strengths for threshold. Results were
combined for each unobserved confounding/instrument strength level and we now present some of these
results.
On performing the analyses using the RD design models, we found that, across all considered band-
widths and treatment effects, data at confounding levels 1 and 2 showed similar results and, in addition,
data at confounding levels 3 and 4 showed similar results for both instrument strengths. This is perhaps
not too surprising since the only difference between these scenarios is in the estimated correlation be-
tween LDL cholesterol level and HDL cholesterol level. Hence, for brevity, we present tables of results
that only include unobserved confounding levels 1 (low level of unobserved confounding) and 3 (high level
of unobserved confounding). Furthermore, we show results for a simulated treatment effect of size 2 and
for chosen bandwidths 0.05 and 0.25. A bandwith of 0.15 was also considered in addition to treatment
effect sizes of 0.5 and 1.09, across all three bandwidths. All results are available in full within the online
supplementary material at the webpage www.statistica.it/gianluca/RDD.
Tables 1 and 2 show results (treatment effect estimates together with associated 95% confidence or
credible intervals) from the simulation studies with treatment effect set to 2 (i.e. treatment with statins
is associated with a reduction of 2mmol/l) for chosen bandwidths 0.05 and 0.25, respectively. We include
results using ATE estimators obtained by estimating the regression model (4) using a standard frequentist
analysis, which we term ∆
freq
β , along with all Bayesian estimators described in Section 3
Bandwidth = 0.05, Treatment Effect Size = 2
ATE Estimators LATE Estimators
IV Confounding ∆freqβ ∆
wip
β ∆
sip
β LATEunct LATEflex LATEcnst
Strong 1: LOW -1.74 -1.86 -1.87 -2.10 -2.10 -2.10
(-1.98, -1.51) (-1.98, -1.74) (-1.99, -1.74) (-2.25, -1.95) (-2.26, -1.96) (-2.24, -1.95)
3: HIGH -0.74 -0.89 -0.90 -2.20 -2.20 -1.75
(-1.08, -0.41) (-1.02, -0.76) (-1.03, -0.76) (-2.59, -1.83) (-2.59, -1.83) (-2.03, -1.48)
Weak 1: LOW -1.01 -1.16 -1.17 -2.19 -2.18 -1.84
(-1.31, -0.72) (-1.29, -1.03) (-1.30, -1.04) (-2.49, -1.91) (-2.48, -1.90) (-2.07, -1.62)
3: HIGH 0.05 -0.08 -0.09 -45.72 -15.75 -0.51
(-0.16, 0.25) ( -0.20, 0.04) ( -0.21, 0.03) (-311.52, 207.84) ( -87.39, 29.38) ( -1.23, 0.20)
Table 1: Simulation study results over 100 simulated datasets, for various confounding scenarios and
instrument strengths for threshold. Intervals are 95% credible intervals or, for non-Bayesian estimates,
95% confidence intervals. Treatment effect size = 2, bandwidth = 0.05.
Examining Tables 1 and 2, we see that the Bayesian LATE estimators generally capture the true
value of the treatment effect (-2.00) and provide plausible 95% credible intervals for both confounding
levels where threshold is a strong instrument for treatment and for the low unobserved confounding level
where threshold is a weak instrument for treatment. In general, both Bayesian and non-Bayesian ATE
estimators do not tend to reflect the true treatment effect, especially as the unobserved confounding level
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Figure 4: Plots in the left hand column show risk vs. simulated LDL cholesterol level, those in the central
column show risk score (bin mid-point) vs. sample mean LDL cholesterol level and those in the right-
hand column show risk score (bin-midpoint) vs. estimated probability of treatment. Plots are shown for
different levels of confounding using simulated datasets with a treatment effect of size 2 and threshold
acting as a strong instrument for treatment. A dashed vertical line indicates the threshold level.
Bandwidth = 0.25, Treatment Effect Size = 2
ATE Estimators LATE Estimators
IV Confounding ∆freqβ ∆
wip
β ∆
sip
β LATEunct LATEflex LATEcnst
Strong 1: LOW -2.02 -1.98 -1.98 -2.26 -2.26 -2.26
(-2.17, -1.87) (-2.08, -1.88) (-2.08, -1.89) (-2.38, -2.14) (-2.38, -2.14) (-2.37, -2.14)
3: HIGH -0.97 -0.94 -0.94 -1.90 -1.90 -1.78
(-1.27, -0.67) (-1.04, -0.83) (-1.05, -0.84) (-2.14, -1.66) (-2.14, -1.66) (-1.99, -1.56)
Weak 1: LOW -1.25 -1.24 -1.25 -2.11 -2.10 -1.92
(-1.47, -1.04) (-1.35, -1.14) (-1.35, -1.14) (-2.31, -1.91) (-2.31, -1.91) (-2.09, -1.75)
3: HIGH -0.20 -0.18 -0.19 -25.28 -22.85 -2.51
(-0.31, -0.08) ( -0.27, -0.08) ( -0.28, -0.09) (-49.48, -10.15) (-48.68, -9.12) ( -3.88, -1.22)
Table 2: Simulation study results over 100 simulated datasets, for various confounding scenarios and
instrument strengths for threshold. Intervals are 95% credible intervals or, for non-Bayesian estimates,
95% confidence intervals. Treatment effect size = 2, bandwith = 0.25.
increases and the strength of threshold as an instrument weakens. An exception is when the bandwith
is large (0.25), the level of unobserved confounding is low and the threshold is a strong instrument for
treatment. This may be expected as the RD design might be considered almost sharp where threshold is
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Figure 5: Plots in the left hand column show risk vs. simulated LDL cholesterol level, those in the central
column show risk score (bin mid-point) vs. sample mean LDL cholesterol level and those in the right-
hand column show risk score (bin-midpoint) vs. estimated probability of treatment. Plots are shown for
different levels of confounding using simulated datasets with a treatment effect of size 2 and threshold
acting as a weak instrument for treatment. A dashed vertical line indicates the threshold level.
a particularly strong instrument for treatment. In addition, a relatively large bandwidth of 0.25 ensures
that there are many treated individuals above the threshold and many untreated individuals below the
threshold and, in such cases, an ATE estimator may be considered appropriate. The larger amount of
utilised data for the bandwidth of 0.25 may also explain why the frequentist ATE estimates are more
similar to the Bayesian ATE estimates in Table 2 when compared to those in Table 1. In general, there
is some bias in most estimates, possibly as a result of different sources of noise incorporated into the
simulation set-up, together with unobserved confounding and changing instrument strength.
Where unobserved confounding is high and the threshold is a weak instrument for treatment, we
see that all estimators behave in an unpredictable manner and fail to estimate the treatment effect
accurately. This is not surprising, since the plots presented in Figures 4 and 5 implied that an RD design
was not appropriate for these scenarios, since the design becomes too fuzzy for the modelling techniques
presented to be applicable. Similar problems are seen in simulation studies investigating the effect of
weak instruments with unobserved confounding [21].
5.1 Sensitivity to prior specification
We considered a number of prior specifications in this work. In situations where such information was
available, for example the possible size and nature of the effect of statins on LDL cholesterol levels
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based on clinical trial results and/or expert GP knowledge, we attempted to account for this. Where
less information was available, as in the case of the probabilities in the denominator for the LATE, we
attempted to understand the sensitivity of results to prior specification.
Overall, the effect of the prior information appears to be negligible for the ATE, with the ∆wipβ and
∆sipβ ATE estimators producing similar estimates across all scenarios and for both bandwidths. Similarly,
there are no obvious differences between the LATEunct and LATEflex estimators under these different
prior distributional assumptions. The LATEcnst estimator yields a slightly higher estimate than both the
LATEunct and LATEflex where there is a high level of unobserved confounding (Level 3) and threshold
is a strong instrument for treatment and also where there is a low level of unobserved confounding and
threshold is a weak instrument for treatment. This is due possibly to the size of the denominator in this
estimator, which is always slightly bigger than those seen in the other two Bayesian LATE estimators.
We fixed the minimum size of denominator by imposing at least 200 more treated above than below the
threshold. Thus, even if the denominator is typically greater that this minimum, on average over all
the simulations, this will result in a larger LATE. This difference is more pronounced in the case of the
smaller 0.05 bandwidth than where a bandwidth of size 0.25 was used. This feature of the LATEcnst
may also explain why this estimator produced a reasonable estimation of the treatment effect where
unobserved confounding is high and threshold is a weak instrument for treatment, using a bandwidth of
0.25 only (Table 2). Overall, flexible priors seem to provide the most reliable results for LATE estimators
in situations where, based on the exploratory plots, an RD design is deemed appropriate. In these cases
when a treatment effect is present, the effect is recovered even when the IV is weak or, in the case of a
strong IV, when the level of unobserved confounding is high.
6 Discussion
6.1 Critical issues
6.1.1 “Local” vs “global” effect
An apparent drawback of the RD design is the “local” nature of the causal estimate, i.e. there is
no guarantee that the causal effect is the same over the whole range of the risk score. If the aim
of estimating the causal effect is to compare it to the results of trials and to determine whether the
prescription guidelines are effective, the local nature is not a disadvantage. Rather it will highlight
whether the guidelines need to change if the results are starkly different from those of a (well conducted)
trial. Furthermore, while trials may indicate that the effect of statins is constant across strata of age,
sex and initial cholesterol levels, there is no reason to assume that this applies across risk scores in the
general population treated by GPs, especially when partial compliance of patients to prescriptions is to
be expected. In Section 6.2 below we discuss how multiple thresholds might be used to determine whether
the effect is constant across the range of the assignment variable.
6.1.2 Compliance and adherence
In the context of the case study on which our simulations are based, we have two types of “compliance”.
One is the adherence of the GP to the prescription guidelines, which we have assumed to be partial, in
our simulations. The second is the compliance of the patient to the treatment prescription, which in
contrast we have assumed is perfect. In real data, this is hardly ever the case: many patients do not take
statins when they have been prescribed.
This aspect also relates to the fact that the LATE estimates a causal effect of a treatment in a
population defined by the fact that the GP adhered to the prescription guidelines. We can ask two
questions here. First; are patients whose GPs adhere to guidelines comparable to those whose GPs
have alternative strategies? Second; given that we are interested in comparing the RD design results
from primary care to those of RCTs, are RCT participants comparable to patients whose GPs adhere to
guidelines?
The first question means we need to understand whether GPs who prescribe according to the guidelines
have patients that are systematically different from those who have GPs with alternative treatment
strategies. There might be circumstances where this is the case, e.g. if different primary care trusts have
different treatment “cultures” as well as different patient populations. Another context where this might
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be the case is if ‘strictly adherent’ GPs prescribe only according to guidelines whilst ‘non-adherent’ GPs
do not and they serve different populations. It is hard to believe either of these would be true, especially
given the fact that the guidelines are nationwide and any individual quirks of GPs would probably even
out over the population. Thus, we are reasonably confident that the LATE is informative about the
general primary care population.
In answer to the second question, we must consider that individuals recruited into an RCT are often
selected on the basis of characteristics that make them more likely to comply and that a primary care
population will not necessarily be similar in those respects. Thus, we might expect that if we do not
take into account the probable lack of patient compliance, we would see a smaller effect size for statins
in primary care than in RCTs. In order to deal with this in future work, we will focus on subgroups of
primary care patients who can be considered in some way exchangeable with RCT recruits.
6.2 Future work
This leads us into the potential problem with Assumption 5 which is necessary to identify the LATE.
This assumption states that there are no GPs whose prescription strategy is to refuse to adhere to the
guidelines. This only makes sense if we believe that GPs have treatment strategies in place before seeing
patients and that they act according to these strategies. While this seems plausible when referring to GPs,
this is not always the case when applied to patient compliance. In this case, we would be requiring that
patients have strategies regarding compliance to taking medication in place before they are prescribed
and that they act in accordance to these strategies. Moreover, that there are no patients whose strategy
it is to “defy” the prescription. Both aspects of the assumption are less credible as patients are less likely
to have strategies and there are likely to be patients who will try to do the opposite of what they are
“told”. We mention this here in order to support our use of the LATE and to distinguish it from the
more common situation of patient compliance where it is used and potentially less reliable. In dealing
with patient compliance we recommend limiting the RD design to those patients whom we consider
exchangeable, so that we may not need to introduce additional complexity within the models to account
for patient non-compliance. Further work in this respect is required but is outside the scope of this paper.
Our focus has been here on statin prescription, where strong information can be brought to bear in
prior model formulation. With other treatments and outcomes, it may be that there is limited knowledge
regarding the effect of the treatment on the outcome (generally to a specific sub-population of patients)
or of clinical adherence to treatment guidelines, but that there exists a vast amount of real observational
data in primary care. We believe that it would be useful to apply Bayesian RD methods in such a scenario
to combine limited evidence-based and clinical prior beliefs with actual observed data in an effort to assess
treatment effects in clinical practice and perhaps inform whether or not further trials/experiments should
be considered.
We believe that the RD design has a great potential in primary care. We can imagine that in the future,
trial results will be augmented by planned RD designs with thresholds at different levels of the assignment
variable in order to determine where in disease progression the treatment is most effective in primary
care as well as having a more realistic basis for cost-effectiveness analyses. This is particularly relevant
when the treatment targets individuals who are likely to be extreme and under-represented in trials, or
when the treatment is for specific subgroups of the population, such as terminally ill patients. Additional
model assumptions or adjustments may be required when fitting an RD design to such subgroups.
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